Today in Medicine: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Medicine.

Press releases published on September 30, 2026

8 hours ago

Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

Indeterminate GlobeNewswire

Sep. 30, 2026

The Patient Digital Twin Platform Market is projected to grow at a CAGR of 34.5% by 2030

Indeterminate EIN Presswire

8 hours ago

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

Indeterminate GlobeNewswire

8 hours ago

Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards

Indeterminate GlobeNewswire

Sep. 30, 2026

Brookdale Outlines Its Continuum of Care for National Recovery Month

Indeterminate EIN Presswire

8 hours ago

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Indeterminate GlobeNewswire

8 hours ago

DiFusion Activates Operating Board to Scale Therapeutic Biomaterials Platform

Indeterminate GlobeNewswire

8 hours ago

Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine

Indeterminate GlobeNewswire

8 hours ago

Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure

Indeterminate GlobeNewswire

8 hours ago

AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450

Indeterminate GlobeNewswire

8 hours ago

Rezera Announces Phase 1 Results for Trabzanoflast, which was Generally Well Tolerated and Demonstrated High Central Nervous System Exposure (CNS)

Indeterminate GlobeNewswire

8 hours ago

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

Indeterminate GlobeNewswire

8 hours ago

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

Indeterminate GlobeNewswire

8 hours ago

Immutep Receives ~A$0.86 Million R&D Tax Incentive

Indeterminate GlobeNewswire

8 hours ago

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

Indeterminate GlobeNewswire

8 hours ago

BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Indeterminate GlobeNewswire

8 hours ago

Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update

Indeterminate GlobeNewswire

8 hours ago

MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

Indeterminate GlobeNewswire

8 hours ago

CURE ALZHEIMER’S FUND AWARDS $6.4 MILLION TO CARDINAL FAMILY SCHOLARS ADVANCING ALZHEIMER’S RESEARCH

Indeterminate GlobeNewswire

9 hours ago

Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development

Indeterminate GlobeNewswire